In India, GLP-1 medicines for obesity are meant to be prescribed only by an endocrinologist or an internal medicine specialist, according to the Government's own answer in Parliament. A Press Information Bureau backgrounder goes slightly further and names cardiologists as well. This is not a change to the law that every doctor learns in medical college. It sits in the fine print of how three specific weight-management drugs were approved for sale, and it is enforced mainly on the pharmacy that dispenses the medicine rather than on the doctor who writes the prescription.

• CDSCO's approval conditions restrict GLP-1 obesity prescriptions to endocrinologists and internal medicine specialists.
• This is not a new provision in the Drugs and Cosmetics Act but a condition attached to these specific product approvals.
• A PIB backgrounder also names cardiologists, but this cannot be confirmed in a primary CDSCO approval document.
• The restriction is enforced mainly through pharmacy licensing, not through direct action against the prescribing doctor.
• The National Medical Commission register confirms a doctor's registration but does not reliably display specialty.

For the obesity indication, prescribing is restricted to endocrinologists and internal medicine specialists. In a written reply to Rajya Sabha Unstarred Question No. 2824, answered on 17 March 2026, the Ministry of Health and Family Welfare stated that the three drugs approved for obesity and weight management in India, orlistat, tirzepatide and semaglutide, are "required to be sold in retail on the prescription of endocrinologist or Internal Medicine/ specialists only as per the conditions of approval issued by CDSCO."

A separate PIB backgrounder titled "GLP-1 Drugs Use, Risks, and Regulation," published on 1 April 2026, adds a third specialty, stating that in India the drug "can be prescribed only by endocrinologists, internal medicine specialists and cardiologists." The cardiologist inclusion appears in that backgrounder but has not, on the public record, been traced to any CDSCO approval letter or committee recommendation. It is reported at that level of confidence below.

Endocrinologists and Internal Medicine Specialists

These are the clearly documented specialist categories for prescribing the three medicines approved for obesity and weight management in India. The March 2026 Rajya Sabha answer cites the CDSCO approval conditions for this requirement.

Cardiologists

Cardiologists are also named by the PIB as eligible prescribers in its April 2026 backgrounder. However, this is not mentioned in the March 2026 Parliament answer

General Physicians and Other RMPs

The general Schedule H rules allow medicines to be prescribed by a Registered Medical Practitioner. However, the obesity-specific approval conditions for these products are narrower

The restriction is a condition of marketing approval, not an amendment to the Drugs and Cosmetics Act or its schedules. India's baseline rule is broad: under the Drugs and Cosmetics Act 1940 and the Drugs and Cosmetics Rules 1945, GLP-1 receptor agonists are Schedule H prescription drugs, and the standing requirement is only that they are "not to be sold by retail without the prescription of a Registered Medical Practitioner." Nothing in the Act or Rules says that a particular class of drug may be prescribed only by certain specialties.

The specialty restriction lives one layer down, inside the product-specific approvals that CDSCO issued for these obesity drugs under the New Drugs and Clinical Trials Rules 2019. Those approval conditions are legally binding on the companies that hold the licence and on the pharmacies that sell the product. The PIB backgrounder that most people quote is an official government communication, but by itself it is a description of that position, not a statute or a binding direction in its own right.

For Schedule H drugs in general, yes. But these three obesity drugs are different. Their approval conditions require the prescription to come from an endocrinologist or an internal medicine specialist. A Registered Medical Practitioner (RMP) is anyone listed on a medical register and authorised to practise modern medicine. Under the standard Schedule H rules, any RMP can prescribe these medicines. However, for these three obesity drugs, the approval conditions override that general rule. As a result, a pharmacy may not accept a prescription from a general physician for these specific products.

The clearly documented restriction attaches to the obesity and weight-management indication. The March 2026 Parliament answer names only the three weight-management drugs. Committee minutes from CDSCO's Subject Expert Committee suggest similar specialist-only wording has been used for some diabetes products, such as oral semaglutide, but no Parliament answer or gazette notification establishes that every GLP-1 prescribed for type 2 diabetes must come from a specialist. On the public record as of 2026, this remains an open question for the diabetes indication.

Cardiologists appear on the list in the PIB backgrounder, but that inclusion cannot be traced to a primary CDSCO document. The Parliament answer mentions only endocrinologists and internal medicine specialists. The most likely explanation is that some GLP-1 products carry, or are expected to carry, a cardiovascular-risk indication, a natural fit for a cardiologist. The World Health Organization's December 2025 global guideline on GLP-1 medicines notes that semaglutide 2.4 mg weekly reduced major cardiovascular events by about 20% in high-risk patients. Even so, no CDSCO approval letter retrieved for this article names cardiologists in its prescriber clause, so the cardiologist entry is best read as reported by PIB rather than confirmed in the underlying instrument.

The pharmacy that dispenses the drug is the party most directly exposed, not the prescribing doctor. The Drugs and Cosmetics Act places its sale offences on the seller. A pharmacy that sells a Schedule H drug without a valid prescription, or against a prescription that does not meet the product's approval conditions, risks action from the State Licensing Authority, up to suspension or cancellation of its sale licence.

A doctor who prescribes outside the named specialties is not committing a drug-sale offence under the Act. Their exposure instead runs through professional conduct under the Indian Medical Council (Professional Conduct, Etiquette and Ethics) Regulations, 2002, which require practice within one's competence and in the patient's best interest. In practice this route is theoretical for GLP-1s: there is no publicly mapped disciplinary case tied specifically to GLP-1 prescribing.

If you want to confirm that a GLP-1 prescriber meets the regulatory requirements, work through these steps:

1. Confirm that the doctor holds a recognised specialist qualification in endocrinology or internal medicine. This is more reliable than the NMC register alone, which does not display postgraduate qualifications.
2. Check registration on the National Medical Commission's register at nationalmedicalcommission.in to confirm the doctor is on the medical roll and authorised to practise modern medicine.
3. Verify specialty through the clinic's own website, a hospital directory, or a professional body such as the Endocrine Society of India or the Association of Physicians of India.
4. Ensure the written prescription clearly identifies the prescriber's specialty on the letterhead or stamp, since pharmacies rely on the prescription to confirm the approval conditions have been met.
5. For online pharmacies, confirm their prescription verification policy before placing an order, as both the Schedule H requirement and the obesity approval conditions apply to the dispensing platform.

The stated reason is patient safety and the risk of misuse without clinical oversight, rather than any detailed published rationale for choosing these specialties. The PIB backgrounder notes that GLP-1 medicines "must be taken under medical supervision" and that misuse without oversight can lead to serious complications, listing side effects that range from nausea and dizziness to pancreatitis and a warning about medullary thyroid cancer.

Indian regulators have paired the prescribing conditions with promotion controls: CDSCO issued an advisory on 10 March 2026 against surrogate advertising of prescription weight-loss drugs, and a public notice in May 2026 directing state drug controllers to step up enforcement against unauthorised promotion and distribution.

None of the Indian primary documents spell out why endocrinologists and internal medicine specialists specifically were chosen. The reasoning is framed broadly, around complex risk profiles and the need for managed care rather than self-medication. That gap is worth stating plainly rather than filling in.

Starting GLP-1 treatment begins with the right specialist assessment.

In India, GLP-1 weight-loss medicines require a prescription from an endocrinologist or internal medicine specialist under CDSCO's approval conditions. Voy India provides a clinician-supervised GLP-1 assessment that connects you with qualified specialists, with ongoing oversight built in, because the approval conditions exist precisely to ensure these medicines are used inside managed clinical care, not outside it.

This article is for general information and education only and is not medical advice, diagnosis, or treatment. GLP-1 and other medications referenced are prescription-only and are appropriate only for certain people under the supervision of a qualified clinician. Do not start, stop, or change any medication based on this article. Please consult a registered medical practitioner about your individual circumstances. Information reflects what was available at the time of review and may change.